🕒 Last update: loading…22/11/2026

Stock Bolt Biotherapeutics, Inc. BOLT

Bolt Biotherapeutics, Inc. — Investlytic score 0/5 on the five criteria.

-
-
0/ 100
Score Investlytic · 5 criteria

Analysis in progress…

Investlytic score: 0/5 criteria met. Data as of 01/11/2026.

  • ❌ Price trend failed
  • ❌ Growth failed
  • ❌ Debt failed
  • ❌ P/E failed
  • ❌ Correction failed

Price trend

Overall trend (8 years): insufficient progression (less than x1.5).

Price change 2021 → 2022: -73.47%

Price change 2022 → 2023: -13.85%

Price change 2023 → 2024: -52.23%

Price change 2024 → 2025: -48.88%

Price change 2025 → 2026: 20.48%

Price change 2026 (year to date): 13.82%

Financial growth

Revenue CAGR (8 years): N/A

Earnings CAGR (8 years): N/A

Growth status: insufficient data or negative trend.

Debt

Debt-to-equity ratio: 0.87

Debt/equity > 0.5 (maximum threshold).

P/E (Price/Earnings)

P/E ratio: -0.40

P/E > 25.0 (maximum threshold).

Correction (6 months)

Current correction: 0.00% from the high over 6 months.

Insufficient correction (< 10.0%).

WATCH
The stock is currently being evaluated.

Criteria of the Investlytic model

- / 5
🔒

Investlytic rating reserved for members

Score out of 100, mechanical verdict of the method (hold, watch, sell: the same for all) and the detail of the 5 criteria · visible with a free account.

02

Price trend

Price & trend

Interactive chart →
Loading chart…

⚖️ Comparison with the market

All stocks →
StockP/EDette/FPRevenue growthRating
Bolt Biotherapeutics, Inc.–0.87–🔒
Femasys Inc.–0.80+16.2 %–
Geratherm Medical AG–0.13−1.2 %–
SpineGuard S.A.–0.27+1.6 %–
Aelis Farma S.A.–1.49+49.1 %–

Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.

03

Detailed analysis · Price trend

-

🔒

Reserved for members

Global model trend and annual price variations · visible with a free account.

04

Revenues & profits

Revenue and net income

🔒

Reserved for members

Chart of revenues and net income over 8 periods · real data, no estimates.

05

Financial indicators

🔒

Reserved for members

18 financial indicators analyzed by groups of criteria: valuation, profitability, growth, solidity, dividend, and momentum.

06

Annual financial statements

Fiscal yearRevenueNet income Net marginEPSRevenue growth
🔒

Reserved for members

Complete annual financial statements: revenue, net income, margin, and EPS over 8 fiscal years.

+

Key reported figures

Revenue, net income and net margin reported by Bolt Biotherapeutics, Inc. over the latest fiscal years.

Revenue
7.7 m USD
fiscal year 2025
Net income
-33.4 m USD
fiscal year 2025
Net margin
-433.7 %
fiscal year 2025
Average annual growth
+101.6 %
Revenue growth over 5 years
Market cap
12.8 m USD
Fiscal yearRevenueNet incomeNet marginRevenue growth
2020231,000-60.7 m-26,289.2 %n/a
20211.3 m-98.6 m-7,824.7 %+445.5 %
20225.7 m-88.1 m-1,537.8 %+354.7 %
20237.9 m-69.2 m-878.6 %+37.5 %
20247.7 m-63.1 m-820.8 %-2.4 %
20257.7 m-33.4 m-433.7 %+0.1 %

Amounts converted to USD. Source: published annual accounts, collected on 20/11/2026.

+

Accounts and financial health

Balance sheet and cash flow published by Bolt Biotherapeutics, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).

Overview
fragile accounts
according to Altman Z, Piotroski and net debt
Altman Z-score
-20.65
risk zone (below 1.81)
Piotroski Score
1 / 9
0 to 3: fragile accounts
Net Debt / EBITDA
-0.28 x
net cash
Fiscal year20212022202320242025
Cash and investments186 m169 m102 m47.3 m27.5 m
Total Debt24.4 m22.6 m20.2 m25.2 m23.0 m
Net Debt-3.0 m13.4 m9.4 m18.0 m11.3 m
Equity250 m172 m113 m57.2 m26.5 m
Total assets308 m228 m160 m99.6 m56.7 m
Operating cash flow-57.1 m-76.5 m-69.5 m-61.3 m-39.9 m
Investments (capex)2.3 m2.0 m206,00041,00072,000
Free cash-flow-59.4 m-78.5 m-69.7 m-61.3 m-39.9 m
Share buybacks00000
Dividends paid00000

Amounts in USD, currency of the published accounts.

Trailing 12-month ratios

Price / earnings (P/E)-0.35 x
Price / book value1.16 x
Return on Equity (ROE)-154.1 %
Return on Invested Capital (ROIC)-86.2 %
Net margin-1,027.9 %
Debt / equity2.44 x
Current ratio2.05 x
Free cash-flow yield-188.0 %

Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 21/11/2026.

+

Analyst consensus and forecasts

What the financial analysts covering Bolt Biotherapeutics, Inc. publish: ratings, price targets and earnings forecasts.

Majority rating
hold
8 analysts

Breakdown of ratings

strong buy 0buy 3hold 5sell 0strong sell 0

Price targets: published for companies listed in the United States only.

Track record against expectations: reported EPS above consensus 6 times over the last 12 releases.

Source: ratings and forecasts published by analysts, collected on 21/11/2026. An analyst rating or target is not a guarantee.

+

Who owns the stock

Free float, institutional investors, large funds, executives and elected officials: declared positions in Bolt Biotherapeutics, Inc.

Large funds tracked
7
hold the stock as of 2026Q2
Executives (insiders)
5 / 9
5 purchases, 9 sales in 130 days

Large funds tracked

FundSharesValue (USD)Weight in the fundChangeQuarter
Citadel Advisors113,806438,1540.0 %+1,025.8 %2026Q2
Renaissance Technologies98,625379,7060.0 %+27.7 %2026Q2
Geode Capital Management19,11973,6220.0 %-33.6 %2026Q2
Vanguard Group10,17955,7820.0 %-70.3 %2025Q4
BlackRock9,71137,3880.0 %0.0 %2026Q2
Morgan Stanley3,14512,1080.0 %-1.4 %2026Q2
JPMorgan Chase421650.0 %0.0 %2026Q2

Latest insider transactions

DatePersonSideAmount
17/11/2026Coastlands Capital Lppurchase114,998 USD
16/11/2026Coastlands Capital Lppurchase194,924 USD
09/11/2026Coastlands Capital Lppurchase319,000 USD
18/09/2026Yonehiro Grantsale22,169 USD
18/09/2026Nemec Sarahsale13,195 USD
18/09/2026Quinn William P.sale29,555 USD

Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 21/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.

+

PEA and practical information

PEA eligibility
no
head office outside the EU and EEA
Listing exchange
Nasdaq
IPO: 05/02/2021
ISIN code
US0977022039
Workforce
52
full-time employees
Chief executive
William P. Quinn

Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.

?

Frequently asked questions about Bolt Biotherapeutics, Inc.

What is the Bolt Biotherapeutics, Inc. share price?

Latest recorded price: 4.91 USD on 20/11/2026, for a market cap of 12.8 m USD.

What is the revenue of Bolt Biotherapeutics, Inc.?

7.7 m USD for fiscal year 2025, with net income of -33.4 m USD (net margin -433.7 %).

What do analysts say about Bolt Biotherapeutics, Inc.?

Out of 8 analysts: 3 buy or strong buy, 5 hold, 0 sell or strong sell.

Is Bolt Biotherapeutics, Inc. stock eligible for the French PEA?

No: the company is headquartered outside the European Union and the European Economic Area (ISIN US0977022039).

How many employees does Bolt Biotherapeutics, Inc. have?

52 full-time employees according to the latest published profile.

Who runs Bolt Biotherapeutics, Inc.?

William P. Quinn is the company's chief executive.

Which large funds own Bolt Biotherapeutics, Inc.?

As of 2026Q2, among the large funds tracked: Citadel Advisors, Renaissance Technologies, Geode Capital Management, Vanguard Group, BlackRock.

07

Similar stocks